Co-Authors
This is a "connection" page, showing publications co-authored by Jérémie Guedj and France Mentré.
Connection Strength
1.510
-
SARS-CoV-2 viral dynamics in non-human primates. PLoS Comput Biol. 2021 03; 17(3):e1008785.
Score: 0.234
-
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. CPT Pharmacometrics Syst Pharmacol. 2020 09; 9(9):509-514.
Score: 0.224
-
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. Clin Pharmacol Ther. 2020 08; 108(2):188.
Score: 0.221
-
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun. 2018 10 01; 9(1):4013.
Score: 0.197
-
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med. 2018 03; 15(3):e1002535.
Score: 0.190
-
Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer. BMC Med Res Methodol. 2017 Jul 17; 17(1):105.
Score: 0.181
-
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
Score: 0.058
-
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response. J Antimicrob Chemother. 2021 01 01; 76(1):277-279.
Score: 0.058
-
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother. 2020 09 01; 75(9):2376-2380.
Score: 0.056
-
Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses". Antimicrob Agents Chemother. 2018 01; 62(1).
Score: 0.047
-
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017 02; 11(2):e0005389.
Score: 0.044